What Are Wall Street Analysts' Target Price for Cencora Stock?

robot
Abstract generation in progress

Cencora, Inc. (COR) is a pharmaceutical distribution and healthcare solutions company that has significantly outperformed the broader market and its industry peers. Analysts have a “Strong Buy” consensus rating for COR, with price targets suggesting further upside potential. The company recently reported strong fiscal Q1 2026 results, beating revenue and EPS expectations.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)